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Abstract
Background: Osteoporotic fractures are common and are associated with increased morbidity,
mortality and health care costs. The most effective way to moderate increases in health care costs
and the sickness and premature death associated with osteoporotic fractures, is to prevent
osteoporosis. Several lines of evidence suggest that nitrates, drugs typically prescribed for the
treatment of angina, may be effective in preventing postmenopausal osteoporosis.
Methods: We have designed a multicentre randomized controlled trial to determine the effects
of nitrates on bone. The trial consists of two studies. The objective of the first study is to determine
whether isosorbide mononitrate at 20 mg/day or nitroglycerin ointment at 15 mg/day leads to
fewer headaches. The nitrate that is best tolerated will be used in a second study with one main
objective: To determine if postmenopausal women with a T-score at the lumbar spine (L1 to L4)
between 0 and -2.0 randomized to two years of treatment with intermittent nitrates have a greater
increase in spine bone mineral density as compared to women randomized to placebo.
We hypothesize that: 1. Women will report fewer headaches when they are randomized to
intermittent nitroglycerin ointment at 15 mg/day compared to intermittent oral isosorbide
mononitrate at 20 mg/day, and, 2. After two years, women randomized to intermittent nitrates will
have a greater percent increase in lumbar spine bone mineral density compared with women
randomized to placebo.
Discussion: We have completed our pilot study and found that transdermal nitroglycerin was
associated with fewer headaches than oral isosorbide mononitrate. We are currently recruiting
patients for our second main study.
1.0 Background
1.1 The burden of illness due to osteoporosis
Osteoporosis (OP) is characterized by a reduction in bone
mass and disruption of skeletal microarchitecture leading
to an increased susceptibility to fracture with minimal
trauma. In Canada, one in four women have OP and in
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1993 the total expenditure for fractures was in excess of
1.3 billion dollars [1,2]. The average length of stay in an
acute care hospital after a hip fracture is three weeks; one
of four patients must remain in long-term care institu-
tions for at least one year; and one of three returns home
but must depend on other people or devices for mobility.
Furthermore, after a hip fracture there is up to a 20%
increased risk of mortality [3].
As elderly men and women are the fastest growing group
in the world and the incidence of OP fractures increases
exponentially with age, the number of men and women
with OP fractures is expected to increase dramatically over
the next 50 years in Canada and world wide [3]. Assuming
current demographic trends continue, the annual inci-
dence of hip fractures worldwide could exceed 21 million
in 2050 [4]. The most effective way to moderate increases
in health care costs and the sickness and premature death
associated with OP fractures, is to prevent OP.
Pharmacologic agents to prevent OP include estrogen
replacement therapy (ERT), bisphosphonates (alendro-
nate, risedronate, and etidronate), and selective estrogen
receptor modulators (raloxifene). These medications
decrease bone resorption. The resultant unopposed bone
formation increases bone mineral density (BMD) and
decreases fracture rates. Each medication has adverse
effects, often resulting in discontinuation. For example, a
randomized controlled trial (RCT) of the bisphosphonate
alendronate reported that at 2 years, 60% of participants
were adherent [5]. Bisphosphonates, if taken improperly,
can cause gastrointestinal irritation and esophageal ulcer-
ation [6,7]. In addition, bisphosphonates cannot be pre-
scribed for patients with impaired renal clearance, yet
these patients are at particularly high risk for fractures [7-
10].
Estrogen (with or without a progestin) reduces the risk of
all types of fractures by 25–33% but with risks that out-
weigh its potential benefits for fractures in the vast major-
ity of women [8]. Raloxifene is associated with a 3-fold
increase in thromboembolic disease, an increase in hot
flushes, leg cramps, leg swelling, and an influenza-like
syndrome [9,10].
Pharmacologic treatments are expensive: raloxifene and
bisphosphonates cost > $700 Canadian/year, are either
unavailable or unaffordable outside of North America
and Western Europe, and of uncertain safety when used
long-term (> 10 years). The limitations of the current ther-
apies have fuelled interest in alternatives. An optimal
agent would be one that decreases bone resorption while
also increasing bone formation to have maximal effects
on BMD and ultimately fracture, is convenient to take,
inexpensive, has minimal adverse effects, is safe for long-
term use, and is available world wide. One potential agent
is nitric oxide in the form of organic nitrate, the subject of
this randomized trial.
This randomized trial consists of two studies. The objec-
tive of the first study is to determine whether isosorbide
mononitrate (ISMO) at 20 mg/day or nitroglycerin oint-
ment (NTG) at 15 mg/day results in fewer headaches. The
nitrate that is best tolerated will be used in a second study
with one main objective: To determine if postmenopausal
women with a T-score at the lumbar spine (L1 to L4)
between 0 and -2.0 randomized to two years of treatment
with intermittent nitrates have a greater increase in spine
BMD as compared to women randomized to placebo.
1.2 Nitric oxide influences osteoclast and osteoblast 
activity
Nitric oxide (NO) is a short-lived free radical involved in
the regulation of many physiological processes, including
bone remodeling [11,12]. There are three sources of NO
(Figure 1). First, NO can be generated by nitric oxide syn-
thase (NOS) from molecular oxygen and the terminal
Sources of nitric oxide Figure 1
Sources of nitric oxide.
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nitrogen of the amino acid L-arginine [12,13]. Second,
NO can be generated nonenzymatically from nitrite in the
acid environment of the stomach. Third, organic nitrates
(e.g. nitroglycerin, isosorbide dinitrate, ISMO) can act as
NO donors [14]. In vitro studies consistently demonstrate
that NO has a biphasic effect on osteoclast activity and
bone resorption [15-19]. Adding a NOS inhibitor to bone
cell cultures results in low concentrations of NO and
potentiates bone resorption. In contrast, adding NO to
bone cell cultures results in high concentrations of NO
and decreases osteoclast maturation and bone resorbing
activity [20-23]. The effects of NO on osteoblasts and
bone formation are less well characterized. Some, but not
all, studies have found that low concentrations of NO
stimulate osteoblast growth and differentiation and
extremely high concentrations inhibit osteoblast growth
and differentiation [24].
1.3 The effect of nitric oxide on rodent bone
NTG ointment, a NO donor, prevents bone loss in rats
[25]. Ovariectomized rats were treated with vehicle, 17-
beta estradiol, NTG ointment, or a combination of 17-
beta estradiol and NTG. Compared with baseline, treat-
ment with NTG increased BMD in ovariectomized rats
(20% ± 3%) to levels similar to those found in sham oper-
ated rats (25% ± 2%) and the increase in BMD in ovariec-
tomized rats treated with NTG ointment (20% ± 3%) was
greater than the increase in ovariectomized rats treated
with vehicle (8% ± 3%) (Table 1). This suggests that
nitrates, which act as NO donors, might preserve or even
increase bone mass.
1.4 The effect of nitric oxide on bone – human studies
In 1998, we began investigating the relationship between
the use of nitrates and BMD in humans using data from
the Study of Osteoporotic Fractures (SOF); a multicentre,
prospective, observational study of 9704 ambulatory,
Caucasian women, aged 65 years and older [26,27]. We
hypothesized that women taking nitrates intermittently
would have significantly higher bone mass than those
who took nitrates continuously. Continuous exposure to
organic nitrate causes tachyphylaxis to its vascular effects.
Data from the cardiovascular literature report tachyphy-
laxis to nitrates with increasing frequency of dose [28].
Tachyphylaxis to nitrates may develop in bone; rats given
NTG ointment daily for 12 weeks had increases in BMD
similar to those with estrogen, yet more frequent admin-
istration abolished any beneficial effects, (Table 2) [29].
We compared hip and heel BMD among nitrate users (391
women) and nonusers (5,827 women) identified by self-
report. Women who reported using ISMO, isosorbide din-
itrate, or NTG more than once a day, every day, were clas-
sified as continuous users (n = 317) and all other women
were classified as intermittent users (n = 74). Compared
with nonusers, nitrate users were more likely to have risk
factors for low BMD [27]. After adjusting for these differ-
ences, and for estrogen use, we found that hip BMD was
2.6% higher and heel BMD was 5.3% higher among inter-
mittent nitrate users compared to nonusers and intermit-
tent nitrate users had greater BMD than continuous users
at both these sites (Table 3). The results were consistent
with our hypothesis that intermittent use of nitrates
improves bone mass while continuous nitrate use may
lead to tachyphylaxis.
There are two potential explanations as to why intermit-
tent nitrate use associated with greater BMD than contin-
uous use. First, women who use nitrates intermittently
may have better health and fewer risk factors for low BMD
than women who require continuous nitrates. However,
adjusting for known for differences in health status did
not mitigate the nitrate effect. Second, the findings may be
due to chance variation. However the results were robust
and statistically significant when we examined BMD at
both the hip and the heel.
The average dose of nitrate among women reporting inter-
mittent use was 0.2 mg/day of NTG. This is well below the
doses required for angina treatment: a typical single dose
is 0.3 mg and daily doses range from 0.3 mg to 0.9 mg.
Among the 74 women reporting intermittent use, the type
(ISMO, isosorbide dinitrate and NTG), the form (sublin-
gual tablet or spray, oral tablets, sustained release tablets,
transdermal patch or ointment), and the dose varied. This
suggests an intriguing possibility that nitrates of any type
Table 1: Effect of conjugated estrogen and transdermal nitroglycerin on BMD in ovariectomized rats 25.
Treatment group, n = 5 for all groups Percent increase in BMD (L2-L4) over 6 weeks
Sham operated 25% ± 2%
Ovariectomized rats 8% ± 3%
Ovariectomized + estrogen 27% ± 5%*
Ovariectomized + transdermal nitroglycerin 20% ± 3%†
Ovariectomized + estrogen + nitroglycerin 22% ± 2%*
*Different than ovariectomized rats at p < 0.005
† Different than ovariectomized rats at p < 0.02Trials 2006, 7:10 http://www.trialsjournal.com/content/7/1/10
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administered intermittently in low doses can increase
BMD.
The next step in our program of research was a RCT com-
paring the effects of placebo and intermittent ISMO on
markers of bone turnover in postmenopausal women. We
randomly assigned 144 women (≥ 3 years postmenopau-
sal with femoral neck BMD T-scores between 0 and -2.5)
to 12 weeks of placebo or intermittent ISMO of 5 mg or
20 mg per day; typically ISMO is prescribed at 20 mg twice
a day. We measured changes from baseline in urine N-Tel-
opeptide (NTx), a marker of bone resorption and serum
Bone Specific Alkaline Phosphatase (BSAP), a marker of
bone formation [30,31].
Our earlier work suggested that the effects of nitrates on
bone was a class effect and as such we did not think the
type of nitrate we chose would result in substantially dif-
ferent effects on markers of bone turnover [26]. We chose
to study ISMO because it is completely and consistently
absorbed, does not have a first pass effect, has linear dose-
dependent pharmacokinetics, and marked dose-depend-
ent hemodynamic effects [32]. We chose doses of 5 mg
and 20 mg; pharmacologic data demonstrate that the
threshold of oral activity of ISMO is 5 mg and the maxi-
mum response is reached with doses of 20 mg [33]. To
prevent tachyphylaxis, we gave ISMO, which is typically
administered twice a day, once a day or intermittently
[26,29].
We studied markers of bone turnover because substantial
changes in markers can occur within 3 months of treat-
ment [34,35]. As such, we were able to assess the potential
utility of intermittent ISMO as a preventative agent for OP
within a short time. Bone markers, particularly resorption
markers, are considered reasonable surrogate end points
for fractures [36-38]. A recent study demonstrated that the
decrease in NTx observed after three to six months of rise-
dronate therapy was significantly associated with the 75%
reduction in vertebral fracture risk at one year and
explained about half of the observed reduction in fracture
risk [39]. The relationship between formation markers
and fractures has not been extensively studied, but some
studies suggest an increase in bone formation markers is
associated with a decrease in subsequent fractures [40].
We found that, compared with placebo, women rand-
omized to intermittent ISMO at 20 mg had a 45.4%
decrease in NTx (95% confidence interval [CI]: 25.8 to
64.9) and a 23.3% increase (95% CI: 8.9 to 37.8) in BSAP.
Women randomized to intermittent ISMO at 5 mg had a
36.3% decrease in NTx (95% CI: 14.8 to 57.8) and a
15.9% increase in BSAP (95% CI: 1.1 to 30.7) (Figure 2)
[30,31]. The decreases in NTx observed with 20 mg of
Table 2: Percent change in lumbar spine BMD in ovariectomized rats after 12 weeks of treatment with nitroglycerin (NTG) ointment 
29.
Treatment Group (n = 5 for all groups) Change in Lumbar Spine BMD
Sham operated 6.3% ± 5.3 *
Ovariectomy (OVX) -2.5% ± 2.0
OVX + estrogen 5.9% ± 3.4*
OVX + 0.2 mg nitroglycerin ointment once a day 6.2% ± 2.8*
OVX + 0.2 mg nitroglycerin ointment twice a day 1.9% ± 2.1
OVX + 0.2 mg nitroglycerin ointment three times a day -0.2% ± 3.3
Table 3: Differences (mean ± SD) in BMD at the total hip and heel in nitrate users and nonusers. Unadjusted and after adjusting for 
estrogen use and baseline differences (26).
Percent difference in BMD (95% CI)
Daily – nonusers Intermittent – nonusers
Hip BMD
Unadjusted 0 (-2.7 to 1.4) 0 (-4.1 to 4.1)
Adjusted* 1.3 (0.14 to 4.1) 2.6 (0.4 to 6.8)
Heel BMD
Unadjusted -2.6 (-5.3 to 0) 0 (-5.3 to 7.9)
Adjusted* 0 (-2.6 to 2.6) 5.3 (2.6 to 11)
*Adjusted for estrogen use and baseline differences (37), which are current alcohol intake, walks for exercise, physical activity, self-reported health 
status, falls in the past 12 months, thiazide and nonthiazide diuretic use, inability to rise from a chair independently and frail on physical examination.Trials 2006, 7:10 http://www.trialsjournal.com/content/7/1/10
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ISMO are similar to those reported with alendronate, rise-
dronate, and estrogen (about 50%) and greater than the
25% decreases reported with raloxifene [40,41]. However,
all of the antiresorptive agents concomitantly decrease
rates of bone formation. In contrast, we observed that
treatment with ISMO resulted in significant increases in
BSAP. The decrease in resorption, coupled with the
increase in formation, suggests that ISMO may reduce
fracture risk to an even greater degree than that seen with
the current antiresorptive agents. The only adverse event
was headache. Headaches, were more common among
women randomized to ISMO (5 and 20 mg groups com-
bined n = 55, 57%) compared with placebo (n = 2, 4%; p
= 0.004). Headaches were no more common among
women taking 20 mg of ISMO (n = 28) than among
women taking 5 mg of ISMO (n = 27; p = 0.7).
Only one other study has examined the effects of nitrates
on bone: an open label trial that randomized 16
oophorectomized women, aged 36 to 45, to intermittent
NTG ointment (15 mg/day) or oral conjugated estrogen
(0.625 mg) [42]. After six months, women taking NTG
ointment had a 40% decrease in NTx and 25% increase in
BSAP compared with baseline. This study, together with
our findings, led U.S. investigators to design a 5 year RCT
to study the effects of intermittent NTG ointment com-
pared with placebo on lumbar spine BMD in 200 post-
menopausal women. The trial is sponsored by the
National Institute of Arthritis and Musculoskeletal and
Skin Disease (NIAMS) and is currently recruiting subjects.
The RCT we are conducting differs in many important
ways from the NIAMS study (see section 2.1 below).
2.0 Methods
2.1 Study design
This research proposal consists of two placebo controlled
trials: a four week pilot study and a 27 month main study.
The main study will be preceded by a one week nitrate
run-in phase. Both the pilot and main study will recruit
healthy postmenopausal women, 50 years of age and
older, with lumbar spine BMD T scores between 0 and -
2.0. The aim of the pilot study is to determine the best tol-
erated preparation of nitrate for future studies. We will
assess eligibility for the pilot study by questionnaire,
focused physical examination, electrocardiogram (ECG)
and review of most recent BMD measurements. Subjects
(n = 22) will be randomly assigned to intermittent NTG at
15 mg/day and intermittent ISMO at 20 mg/day, each for
one week. The order of the treatments will be random,
accompanied by a placebo control (identical in sight and
smell to the active treatment). In between each treatment
there will be a two week washout period. Subjects will
record the severity of headaches upon awakening every
day for four weeks using a visual analog scale (VAS). We
will calculate the mean headache score for each subject
over both seven day treatment periods and then the mean
headache score considering all subjects for each of the
NTG and ISMO treatment periods.
The nitrate that is best tolerated will be used in our sec-
ond, main study, whose primary objective is to assess the
effects of intermittent nitrates on spine BMD (L1 to L4).
To limit differential drop out due to headaches the main
trial will follow from a one week nitrate run-in phase;
women who discontinue the nitrate due to headaches will
not enter the main trial. We will recruit 280 women and
assess eligibility by questionnaire, focused physical exam-
ination, ECG, and BMD. We anticipate 17% (48 of 280)
of these subjects will be unable to tolerate nitrates due to
headaches in the run-in phase, leaving 232 subjects for
enrollment into the main study. At the start of the main
study all subjects will undergo BMD testing on the same
densitometer at the main study centre. We will also deter-
mine the total calcium and vitamin D intake, from diet
and supplements, using a modified version of the Block
Percent change in urine NTx and serum BSAP in women ran- domly assigned to 5 or 20 mg of ISMO daily compared with  women assigned to placebo Figure 2
Percent change in urine NTx and serum BSAP in women ran-
domly assigned to 5 or 20 mg of ISMO daily compared with 
women assigned to placebo.
1 -36.3
-45.4
15.9
23.3
-60
-40
-20
0
20
40
NTX
BSAP
Percent 
change 
vs. 
placebo 
5 mg ISMO          20 mg ISMO Trials 2006, 7:10 http://www.trialsjournal.com/content/7/1/10
Page 6 of 14
(page number not for citation purposes)
food frequency questionnaire. This 34-item questionnaire
correlates well (r = 0.76) with the seven day food record
and has been validated in postmenopausal women [47-
49]. Subjects will be given supplements as required so that
all our subjects have an intake of 1500 mg/day of calcium
and 800 IU/day of vitamin D. For the first 3 months after
study entry, subjects will take only calcium and vitamin D
supplements as required (pre-treatment phase). At 3
months, all subjects will have blood and urine samples
taken for measurement of bone turnover markers, will
undergo peripheral quantitative computed tomography
(pQCT) assessments, and will be randomly assigned to
placebo or active treatment, in addition to calcium and
vitamin D. At 3, 12 and 24 months post randomization,
subjects will return to the study centre and provide a fast-
ing blood and second morning urine sample for bone
turnover markers; the unused calcium, vitamin D, and
study medication will be counted and they will receive a
new supply. We will measure BMD and pQCT 12 and 24
months post randomization. The design of the main study
is summarized in Figure. 3.
An alternative design would be a single study on the
effects of three treatments (placebo, NTG, ISMO) on
BMD, bone turnover markers, and pQCT. This design is
inferior to our current approach for several reasons. Three
treatment arms increases the number of subjects required,
and increases recruitment time and study costs. Failure to
identify the best tolerated nitrate prior to a larger, longer
study may result in a large number of drop outs from
adverse events that will reduce study efficiency and
increase costs. Furthermore, 3 treatment arms necessitate
the manufacturing and administration of both placebo
paste and placebo pills, which increases study complexity
and costs. Thus, we are well-justified in starting with a
small short pilot study and then proceeding with the
larger main trial. Three key features of this study that
require further elaboration – the patient population, the
rationale for the pilot study and nitrate run-in phase, and
the outcomes measured – are discussed below.
2.1.1 Patient population: the rationale for studying postmenopausal 
women
While we recognize that men are also at risk for OP, this
RCT will include only postmenopausal women for several
reasons. First, studies of nitrates to date have included
only postmenopausal women. Second, after menopause
in women and age 50 in men, men have higher estradiol
levels than women and this difference may influence the
effect of nitrates on bone [50]. A third issue is the rate of
bone turnover; women, particularly in the first five years
after menopause, have higher rates of bone turnover than
men with OP [51-53]. These differences in bone turnover
rates may lead to heterogeneity with respect to the BMD
response to nitrates and may limit the power of our study.
In particular, postmenopausal women randomized to pla-
cebo may have decreases in BMD while men may not.
2.1.2 The pilot study and nitrate run-in phase
No published studies compare nitrate preparations with
respect to the frequency and severity of headaches. In our
earlier study, 16 of the 96 (17%) women randomized to
ISMO dropped out due to headaches compared with 2 of
48 (4%) women in the placebo [30,31]. All the women in
the ISMO group who dropped out due to headaches did
so within two days of randomization. The severity of the
Table 4B: Required sample size to test all secondary hypotheses in main study.
Hypothesis Clinically Important Difference Standard Deviation of Change Subjects, per group
Hip BMD will be higher in 
treatment group*
2% 4.5% (5, 59, 62, 80, 81) 107
NTx will lower in treatment 
group†
15% (69, 87–89) 28% (30, 35) 105
BSAP will be higher in treatment 
group†
15% (69, 87–89) 25% (30) 105
Headaches due to nitrates will be 
higher in treatment group**
20% (30) 5% (30) 36
Trabecular bone density by pQCT 
will be higher in treatment group**
10 mg/cm3 (67, 70) 7.5 mg/cm3 (67, 70) 31
* Based on a t-test, assuming a two sided alpha of 0.05 a power of 0.90 and a standard deviation of change in BMD measurements of 4.5%.
† Assuming a repeated measures analysis of variance (75).
** Based on a Student's t test, assuming a two sided alpha of 0.05, a power of 0.90.
Table 4A: Formula used for sample size calculation for pilot study.
n = (Z1-α/2 + Z1-β)2 {1 + (n - 1)ρ}/(n∆2), where n = 7, ρ = 0.2, ∆ =  , β = 0.1.
25
27 78 .Trials 2006, 7:10 http://www.trialsjournal.com/content/7/1/10
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headaches determined drop out such that a woman with
one day of severe headache was five times more likely to
drop out than a woman with mild headaches for several
days. Headaches were most severe upon awakening and
subsided over the day. All headaches resolved within 24
hours of discontinuing the treatment assignment.
In the open label trial discussed earlier women were given
15 mg/day of NTG ointment and no headaches were
reported [42]. Although cross-trial comparisons are prob-
lematic, this difference suggests that NTG ointment is bet-
ter tolerated than oral ISMO. One explanation relates to
differences in pharmacokinetics; compared with NTG
ointment, ISMO results in a much longer exposure to NO
[54-57]. Alternative explanations relate to differences in
subjects (the open label trial studied young women with
surgical menopause who had hot flashes, while we stud-
ied healthy older postmenopausal women), or in ascer-
tainment of adverse events (the open label trial relied on
self-report whereas we regularly inquired about head-
aches). Because there is considerable uncertainty about
the relationship of nitrate preparation and headaches, our
pilot study will focus on which of NTG or ISMO gives the
least headaches.
To minimize differential drop out the main trial will be
preceded by a one week nitrate run-in phase. All women
eligible and willing to enter the trial will be instructed to
take the nitrate, identified in the pilot as the best tolerated,
for one week (as noted above women who develop head-
aches do so within 48 hours of taking the drug). Women
who do not develop headaches will enter the main trial
and, after 3 months of calcium and vitamin D (pre-treat-
ment phase), will be randomized to placebo or treatment.
2.1.3 The intervention: rationale for the nitrate preparation, dose, 
and frequency of administration
Although several other forms of nitrates (e.g. transdermal
patch, sublingual sprays) are available, we chose to study
NTG ointment (15 mg/day) and oral ISMO (20 mg/day)
because these are the only agents for which data on the
safety and tolerability in healthy postmenopausal women
exist. Moreover, the only studies that have reported
changes in bone turnover markers have used either NTG
ointment or ISMO. We will study the 20 mg dose of ISMO
as our earlier work found that this dose was associated
with the greatest change in bone turnover markers
[30,31]. There was no difference in headache incidence
among women randomized to 5 mg compared to 20 mg.
The 20 mg dose is marketed and readily available; this will
be important if we use ISMO in a RCT of nitrates for frac-
ture prevention.
We will study the 15 mg/day dose of NTG ointment. This
dose was used in the open label trial of NTG for the pre-
vention of oophorectomy induced bone loss [42]. The 15
mg/day dose was based on dose response studies in
rodents: a dose of 0.2 mg/kg/day of NTG was associated
with the greatest change in bone turnover markers
[25,29,58].
We considered using the NTG patch instead of NTG oint-
ment. The NTG patch has a major disadvantage: it has a
long (24 hour) average duration of action and, therefore,
may cause tachyphylaxis to the bone effects of nitrate. In
contrast, the ointment has a much shorter (6 hour) aver-
age duration of action so that once daily administration
avoids development of tachyphylaxis. We recognize that
ointment is more difficult to apply than a transdermal
patch and might stain clothing. However, we have used
the ointment in 18 women in our pilot study with no
mention by women of messiness or staining of clothes.
Design of the main trial Figure 3
Design of the main trial. *The main trial will be preceded by a 
one week nitrate run-in phase. Subjects who do not develop 
headaches during the run-in phase will then enter the main 
trial. The main trial consists of a 3 month pre-treatment 
phase with calcium and vitamin D. At 3 months subjects are 
randomized to treatment of placebo.
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We will administer both NTG and ISMO once a day i.e.
intermittently. While other dosing frequencies may
increase BMD (e.g. continuous dosing, or even once
weekly dosing), data from both the cardiovascular litera-
ture and our observational study suggest that too frequent
dosing (e.g. ISMO 20 mg twice a day or NTG every eight
hours) is associated with tachyphylaxis while pharmaco-
logic studies suggest that too infrequent dosing (e.g. less
than once a day) results in increased frequency and sever-
ity of headaches. Thus, once daily or intermittent admin-
istration of nitrates will give the greatest change in BMD
and the fewest headaches.
As noted earlier above only one other study (funded by
NIAMS) is examining the effects of intermittent nitrates
on bone in vivo. Our study differs from the NIAMS study
in several important ways: 1. We will determine which of
NTG or ISMO is better tolerated in healthy postmenopau-
sal women. This has never been done and is vital, both for
the success of our proposal and for the potential clinical
use of nitrates in future RCT's and clinical practice. 2. We
will determine changes in bone turnover markers in
response to nitrates, and 3. We will evaluate changes in
bone microarchitecture using pQCT. These latter two out-
comes are not being assessed in the NIAMS study, yet
turnover markers and microarchitecture contribute sub-
stantially to fracture risk [9,62,69].
2.2 Trial interventions
Pilot study
Subjects will receive NTG ointment; at 15 mg/day (one
inch of 2% ointment applied to the upper arm) for one
week and ISMO at 20 mg/day for one week. The order of
treatments will be randomized. In between each treat-
ment there will be a two week washout. The washout
exceeds ten half lives of NTG (one hour) and ISMO (five
hours) and will eliminate any carryover effects [54-57].
Subjects who report headaches during the wash out will
be excluded from the second treatment phase and consid-
ered as drop outs in our analysis. We have considered
drop outs in our sample size calculations. Both treatments
will be administered with placebo (tablet or paste, as
appropriate). Subjects will receive standard instructions
on how to take the tablet (at bed time with a glass of
water; as was given in our earlier study) and patch (apply
it first thing in the morning; as was given in the earlier
study).
Main study
Subjects who are eligible and willing to participate in the
main study will complete a standardized, validated, inter-
viewer administered questionnaire designed to collect
general demographics and evaluate factors that have been
demonstrated in prospective observational studies to
influence levels of bone turnover markers, BMD, and frac-
ture risk [27]. The questionnaire will also assess total daily
calcium and vitamin D intake using a modified version of
the Block questionnaire. All subjects will be instructed to
take the nitrate, identified in the pilot study to be the best
tolerated, daily for one week. Subjects who do not
develop headaches during the nitrate run-in phase will
enter the main trial. The first 3 months of the main trial
consist of a calcium and vitamin D pre-treatment phase.
We will determine the total daily calcium and vitamin D
intake from questionnaire and we will provide calcium
carbonate in 500 mg tablets and vitamin D in 400 IU tab-
lets as needed so that the total daily calcium intake for all
study subjects will be 1500 mg and the vitamin D intake
will be 800 IU; these are the intakes recommended in the
recently published guidelines for the prevention and treat-
ment of OP in Canada [70]. Calcium and vitamin D are
the mainstay of all treatment regimens for OP and any
new agent should be evaluated to assess the additional
benefit it would provide. The three month calcium and
vitamin D pre-treatment phase will limit any carryover
effects of nitrates from the nitrate run-in phase. Further,
by providing calcium and vitamin D, we hope to discour-
age subjects who, after being enrolled in an "OP trial",
start taking additional, unreported calcium and vitamin D
(co-intervention). Calcium and vitamin D will be pre-
pared and packaged by the study pharmacist, and instruc-
tions on how to take the supplements and the PI's office
number will be printed on each bottle. Subjects will be
given standard verbal instructions by the PI and reminded
to take the calcium and vitamin D daily with the morning
meal.
All subjects who return to the study centre at three months
will undergo pQCT assessments, have blood and urine
taken for measurement of bone turnover markers, and be
randomly assigned to placebo or active treatment. Sub-
jects will receive a 3 month supply of study medication,
calcium, and vitamin D, and will receive standard verbal
and written instructions on how to take the medication,
calcium, and vitamin D. At 3 months post randomization,
Table 4C: Method for calculated percent change in BSAP and NTx
We will calculate the percent change for BSAP* for each participant as:
Then we will average the percent change over all study participants
*We will perform identical calculations for NTx.
(( ) BSAP at study end   months BSAP at start of randomizat 27 − i ion   months
BSAP at the of randomization
() ) 3
100 ×Trials 2006, 7:10 http://www.trialsjournal.com/content/7/1/10
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subjects will return to the study centre and provide blood
and urine samples for bone turnover markers; unused cal-
cium, vitamin D, and study medication will be collected
and counted, and subjects will be given a nine month sup-
ply of study medication, calcium, and vitamin D. At 12
and 24 months post randomization, subjects will visit the
study centre and provide blood and urine samples for
bone turnover markers; the unused calcium, vitamin D
and study medication will be counted (at the 12 month
post randomization visit we will provide a 12 month sup-
ply of calcium, vitamin D and study medication) and we
will obtain BMD and pQCT assessments (Figure. 3).
2.3 Study subjects
The pilot and main study have identical inclusion and
exclusion criteria.
Inclusion criteria
1. Women aged 50 and older. 2. Lumbar spine BMD (L1
to L4) T score between 0 and -2.0. 3. ≥ 3 years postmeno-
pausal.
Exclusion criteria
1. Prior low trauma hip or vertebral fracture; these subjects
have OP and require treatment. 2. Total hip or femoral
neck T score of < -2.0; these subjects either have OP and
require treatment, or are at increased risk of developing
OP over the course of the main study. 3. Bone disorders
other than osteopenia (e.g. hyperparathyroidism or
Paget's disease); these subjects require treatment. 4. Treat-
ment within six months of study entry with androgen, cal-
citonin, estrogen, progesterone, fluoride in a tablet form,
raloxifene, tamoxifen, etidronate, prednisone or an equiv-
alent at 5 mg/d for 12 months or greater, lithium or anti-
convulsants. These agents can alter levels of bone turnover
markers for up to six months. 5. Alendronate or risedro-
nate use for at least four weeks, within the last three years.
These agents may influence bone remodeling for up to
three years. 6. Current treatment with nitrates. 7. Systolic
blood pressure of ≤ 100 mm Hg or diastolic blood pres-
sure ≥ 110 mm Hg at the baseline screening examination.
8. Abnormal ECG at the baseline screening examination.
9. History of myocardial infarction, angina, valvular or
congenital heart disease. 10. Disabling conditions that
may interfere with follow-up visits. 11. Inability to give
informed consent. 12. Migraine headaches; nitrates can
exacerbate migraines. 13. Hypersensitivity to nitrates.
2.4 Study outcomes
Pilot study
The primary outcome will be mean headache score asso-
ciated with each of intermittent NTG and ISMO use. Sub-
jects will be given four seven day diaries, with a VAS for
each day of both treatment periods and the wash out
period. Subjects will rate their headache upon awakening
on a daily basis; our previous study demonstrated that
subjects randomized to ISMO who developed headaches
reported that the headache was most severe upon awaken-
ing and gradually subsided over the day [43]. The VAS
uses a 100 mm continuous horizontal line with the left
pole labeled "no headache" and the right pole labeled
"terrible headache"; subjects will be instructed to draw a
vertical line intersecting the VAS indicating the severity of
their morning headache. We will calculate the mean head-
ache score with intermittent NTG and intermittent ISMO
for each subject. Then we will calculate the mean head-
ache score for all subjects when taking ISMO and when
taking NTG. The nitrate that gives the lowest mean head-
ache score will be used in our main study. Our earlier
work indicates that the nitrate formulation associated
with the most severe headaches will result in the greatest
number of drop outs [30]. The VAS can detect subtle
changes in subjective complaints (i.e. headache), has doc-
umented reliability, and has been used in several studies
designed to study the effects of NTG ointment on head-
ache in healthy women [56,57].
Main study
The primary outcome will be the change from baseline in
BMD at the lumbar spine over 24 months among women
randomized to treatment compared with women rand-
omized to placebo. BMD will be measured (on the same
machine in all subjects) at the lumbar spine (L1 to L4)
using a Lunar DPX-L bone densitometer (Lunar Corpora-
tion, Madison WI). A single experienced technician, certi-
fied by the International Society of Clinical Densitometry
(ISCD) and blinded to the treatment assignment, will per-
form all BMD measurements. The intraclass correlation
coefficient for BMD measurements is 0.98 [72]. The PI
will be blinded to treatment assignment and will report
the BMD. BMD reporting is objective and based on stand-
ard ISCD criteria.
We will assess four secondary outcomes in the main study:
1. Change from baseline in total hip BMD
This will provide information about the effects of nitrates
on cortical and trabecular bone and ultimately on the
ability of nitrates to prevent hip fractures.
2. Change from baseline in bone formation and bone resorption 
markers
Measuring markers of bone turnover will increase our
understanding of the mechanisms by which intermittent
nitrates increase BMD (i.e. a decrease in bone resorption
and/or an increase in bone formation). We will measure
bone turnover markers three months after initiating cal-
cium and vitamin D because we expect a 10% decrease in
markers with the use of supplements, and the maximal
change in bone markers is typically observed at threeTrials 2006, 7:10 http://www.trialsjournal.com/content/7/1/10
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months [36]. Thus, we will be assessing any additional
effects of intermittent nitrates on markers of bone turno-
ver in women receiving calcium and vitamin D supple-
ments. Urinary NTx will be measured on a second
morning urine sample using a monoclonal antibody tech-
nique (Osteomark) [73]. The intra-assay variability is
7.6% and the inter-assay variability is 4.0%. Serum BSAP
will be measured on a fasting serum sample using a mon-
oclonal antibody technique (Metra Biosystems) [74]. The
intra-assay variability is 5.8% and the inter-assay variabil-
ity is 5.2%. To minimize variability, subjects will be given
written and verbal instructions on how to collect the sec-
ond morning urine sample; for each subject we will collect
all the samples (baseline, three, 12 and 24 month post
randomization) at the same time, and we will store the
blood and urine at -70°C and analyze all the samples
together in a single laboratory. We will compare measures
of bone turnover markers at 3, 12, and 24 months after
randomization using a repeated measure of analysis of
variance [75]. By measuring markers at three months we
will be able to directly compare these results to the find-
ings in our earlier study. By measuring markers at 12 and
24 months we will be able to evaluate to a limited degree,
the question of tachyphylaxis with nitrates. Recall that in
our earlier study we found a decrease in markers of bone
resorption and an increase in markers of bone formation
after 90 days of treatment with intermittent ISMO [30,31].
Measuring markers after one and two years of treatment
will allow us to determine if there is still a marked
decrease in bone resorption and increase in bone forma-
tion; no further changes in markers may indicate that the
effects of nitrates on bone is transient.
3. Adverse events
Adverse events will be assessed using a standardized, vali-
dated interviewer administered questionnaire on a
monthly basis by telephone.
4. Bone microarchitecture
Fracture risk is influenced by both the quantity of bone
(assessed by BMD) and quality of bone. Fracture risk is
influenced by both the quantity of bone (assessed by
BMD) and quality of bone. Indeed, recent reports suggest
that up to 40% of fracture risk is explained by decreases in
bone quality [5,62]. Our results indicate that nitrates
increase bone formation. Exercise and agents, such as
PTH, that form bone add bone to the periosteal surface of
cortical bone; this may also apply to nitrates. Small
increases in the external diameter of bone substantially
increase the bending strength of long bones. Unfortu-
nately, bone density by DXA of the complex structures of
hip and spine have poor resolution of cortical bone edges
and cannot accurately measure the periosteal accretion of
cortical bone. In fact, addition of periosteal bone will
increase the diameter and, therefore, the projected area of
a bone. Since BMD is calculated as total bone mineral
content divided by bone area, an increase in bone diame-
ter may paradoxically tend to decrease BMD! Therefore, it
is essential to use a measurement that precisely measures
cortical dimensions in tubular bone.
Cross-sectional moment of inertia is one of the best bio-
mechanical measurements of the strength of long bones.
Trabecular density also contributes to the strength of
many bones with high trabecular content. All of these fea-
tures can be measured with pQCT [66]. PQCT measures
are precise, with a minimum detectable change for volu-
metric bone density of 0.03 g cm-3 [67,68]. PQCT meas-
urements of volumetric bone density and trabecular bone
texture have been used by researchers at McMaster Univer-
sity to demonstrate that reductions in fracture risk
induced by hormone replacement therapy are due to dep-
osition of bone at the endocortical surface [67]. Statisti-
cally significant responses in density, area and texture
were detected within six months when 21 women starting
therapy were compared with 32 matched controls. Previ-
ous work at McMaster was performed with a second gen-
eration pQCT machine. The investigators at McMaster
have recently obtained a third generation scanner (Stratec
XCT2000) that allows measurements of greater reproduc-
ibility in both the radius (nonweight bearing) and the
tibia (weight bearing). This is particularly relevant with
regard to NO as in vitro studies demonstrate that the nitric
oxide synthase gene promoter is activated in response to
shear stress (equivalent to weight bearing in humans)
[68]. Thus, increased levels of NO that results in decreased
bone resorption may be one mechanism by which weight
bearing prevents bone loss. Our study will test this
hypothesis by comparing pQCT measurements in the
radius (nonweight bearing) and tibia (weight bearing)
among women randomized to nitrates and placebo.
2.5 Sample size
Pilot study
We wish to detect at least 15 units difference in headache
score using the VAS between the intermittent NTG and
ISMO groups, which is consistent with a modest effect
[57]. We assumed a power of 90% and two sided alpha of
0.05, a standard deviation of 27.78 (based on studies
using the VAS to report headaches in healthy women),
[56,57] and a small correlation of 0.5 among the repeated
measurements [77]. Based on these assumptions, the
number of subjects needed for comparing (paired) the
mean headache scores for two groups is 20 subjects (Table
4A). We will increase this number by 10%, to account for
women who develop headaches that continue into the
washout period and cannot go on to the second treat-
ment. Note that this is a conservative approach, in our ear-
lier study all women who developed headaches reported
that when they stopped the treatment the headacheTrials 2006, 7:10 http://www.trialsjournal.com/content/7/1/10
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resolved within 24 hours. Based on these assumptions, we
will require 22 subjects for our pilot study.
Main study
Our primary hypothesis is that, after 27 months, we will
observe a clinically important and statistically significant
increase in lumbar spine BMD, expressed in percent
change from baseline, among women randomized to
treatment compared with placebo. Our sample size calcu-
lation is based on t-test and will allow us to detect a 2%
difference in spine BMD; 2% is the minimal difference
that would justify nitrate treatment as this is the minimal
magnitude of BMD change observed with other accepted
osteoporosis treatments [5,61,62,78,79]. The standard
deviation of change with a 2% difference in BMD ranges
from 4.5% to 6.8% [5,59,62,80,81]. Assuming a standard
deviation of change of 4.5%, a two sided alpha of 0.05
and a power of 0.90 we require 107 subjects per group
[81].
The main trial will be preceded by a nitrate run-in phase
and only women who complete the run-in phase will be
entered into the main trial (see section 2.1aii). Our previ-
ous data indicate that 16 of 96 (17%) women randomized
to ISMO dropped out due to headaches and 6 of the 144
(4%) women did not return to the study centre after ran-
domization and were lost to follow up [42]. Thus we will
"over recruit" by 25% to allow for a 17% drop out in the
run-in phase due to headaches and a 8% loss to follow up
during the main trial. Thus, we will recruit 280 subjects of
whom we anticipate that 232 subjects will complete the
run-in phase and enter the main trial (116 subjects per
group). This sample size will ensure that we observe a
clinically important and statistically significant difference
between the active treatment and placebo group. Our
sample size gives us adequate power to test our secondary
hypotheses (Table 4B).
The estimated 17% drop out rate from headaches in the
run-in phase is conservative as the pilot study will identify
the best tolerated nitrate. We anticipate that less than 1%
of women will drop out from headaches during our main
trial based on the fact that in our earlier trial the majority
of the women who dropped out due to headaches did so
within the first 48 hours.
2.6 Data analysis
Our main analysis will be intention to treat [86]. There
will be no subgroup or interim analysis.
Pilot study
We will use a paired t test to examine for differences in
headache score when subjects are randomized to intermit-
tent ISMO compared to the same subjects randomized to
intermittent NTG.
Main study
For all of the outcomes in our main study we will compare
differences, at 27 months, between the intermittent
nitrate group and the placebo group. To determine the
percent change in total lumbar spine and hip BMD we will
use a Student's t test. We will aim to have follow-up meas-
urements on 100% of subjects randomized and plan to do
an intention to treat analysis including measurements. To
determine the percent change in BSAP and NTx we will
use a repeated measures analysis of variance, after calcu-
lating the percent change in BSAP and NTx for each sub-
ject (see Table 4C). To determine if the incidence of
headaches is higher in the intermittent nitrate group com-
pared to the placebo group we will use a Student's t test.
We will also use a Student's t test to determine if trabecu-
lar density by pQCT is higher in the intermittent nitrate
group compared to the placebo group (Table 4B).
2.7 Trial management
This is be a multicentre trial that will recruit from five
sites: The University Health Network, St. Michael's Hospi-
tal, Women's College Ambulatory Care Centre, Sunny-
brook Health Sciences Centre, and the Hamilton Health
Sciences Centre at McMaster University. As well, we will
confer with national and international experts on the con-
duct of the trial and the interpretation of our data.
All adverse events and significant medical conditions will
be recorded and faxed to the committee for adjudication.
Subjects will be discontinued from the study if they
develop clinical fractures, if their BMD falls below -2.5 at
one-year, or if they develop medical conditions that
necessitate starting nitrates (e.g. developing angina).
3.0 Discussion
We successfully completed our pilot study in August
2005. We found that headaches were significantly lower
when women were randomized to nitroglycerin ointment
compared with oral isosorbide mononitrate. As a result,
the main study is assessing the effects of nitroglycerin
ointment on bone mineral density. To date, we have
screened 310 subjects, 77 have entered the one week
nitrate run in phase, 25 women dropped out after the one
week nitrate run-in phase (19 of these due to headaches)
have dropped out and 52 women are still participating in
the trial.
Nitrates have several advantages over the medications cur-
rently used to prevent and treat OP. Unlike ERT, there
have been no reports of an increased risk of cardiovascular
disease or breast cancer with long-term use of nitrates [43-
46]. Compared with bisphosphonates and raloxifene,
nitrates are generally more available world wide, more
convenient to take, and less expensive. Clearly, further
studies of nitrates are essential.Trials 2006, 7:10 http://www.trialsjournal.com/content/7/1/10
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The value of nitrates for prevention of fracture will require
a randomized blinded trial with a fracture outcome. We
plan to conduct an international trial comparing intermit-
tent nitrates with standard pharmacologic therapy to pre-
vent fractures in women with OP. Prior to the RCT, we
must determine the form of nitrate that is associated with
the least severe headaches and also determine if intermit-
tent nitrates can increase spine BMD. These are the main
objectives of this trial.
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